OMass raises $310M Series C, calls it a step toward 'Britain's Big Biotech'

Oxford-based OMass Therapeutics closed a $310M Series C, calling it 'a fantastic milestone' on its bid to become 'Britain's Big Biotech.' The round gives the rare-disease drug developer 24–36 months of runway.